ovel biomarkers for delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage: cellular microparticles revisited

Austrian Science Fund (FWF) (Austria)0 个研究点目标入组 63 人开始时间: 2014年6月16日最近更新: 2015年1月13日

适应症

试验速览

暂无简介。

•1. Patients of either sex aged between 18?75 years
•2. Signs and symptoms of SAH with an onset within 48 hours before screening irrespective of World Federation of Neurological Surgeons (WFNS) grade (I?V) at admission
•3. A computed tomography (CT) scan shows an aneurysmal bleeding pattern in combination with the presence of an appropriate aneurysm at CT angiography or digital subtraction angiography (DSA)
•4. Women of childbearing potential must have a negative serum pregnancy test

•1. Definite contraindication to magnetic resonance imaging (MRI) (e.g., pacemakers)
•2. History of trauma, cerebral vascular malformation or other non-aneurysmal source of bleeding
•3. Moderate to severe cerebral vasospasm at screening
•4. Known coagulopathies, long-term therapy with platelet aggregation inhibitors or oral anticoagulants
•5. Severe concomitant diseases as well as patients in whom death seems imminent

发起方

Austrian Science Fund (FWF) (Austria)